49 related articles for article (PubMed ID: 29793637)
1. Impact of C-Reactive Protein and Coronary Artery Calcium on Benefit Observed With Atorvastatin.
Blaha MJ; Nasir K; Budoff MJ; Dardari ZA; Blumenthal RS; Pollack S; Reichek N; Guerci AD
J Am Coll Cardiol; 2018 May; 71(21):2487-2488. PubMed ID: 29793637
[No Abstract] [Full Text] [Related]
2. Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials.
Kumar A; Shariff M; Doshi R
Eur J Prev Cardiol; 2020 Dec; 27(19):2138-2141. PubMed ID: 31382809
[No Abstract] [Full Text] [Related]
3. Beyond Framingham and coronary calcium: predicted lifetime risk identifies unfavorable risk trajectories.
Paixao AR; Berry JD
J Nucl Cardiol; 2014 Feb; 21(1):42-5. PubMed ID: 24357399
[No Abstract] [Full Text] [Related]
4. Short and lifetime cardiovascular risk estimates: same wine, different bottles. Do we have the COURAGE to abandon risk scores?
Nasir K; Blaha MJ
J Nucl Cardiol; 2014 Feb; 21(1):46-9. PubMed ID: 24347128
[No Abstract] [Full Text] [Related]
5. Association of Statin Use With Cardiovascular Outcomes by Coronary Calcium: MESA.
Zhou Z; Ong KL; Breslin M; Allison MA; Curtis AJ; Nelson MR
JACC Cardiovasc Imaging; 2020 Apr; 13(4):1094-1096. PubMed ID: 31928940
[No Abstract] [Full Text] [Related]
6. Warranty Period of a Calcium Score of Zero: Comprehensive Analysis From MESA.
Dzaye O; Dardari ZA; Cainzos-Achirica M; Blankstein R; Agatston AS; Duebgen M; Yeboah J; Szklo M; Budoff MJ; Lima JAC; Blumenthal RS; Nasir K; Blaha MJ
JACC Cardiovasc Imaging; 2021 May; 14(5):990-1002. PubMed ID: 33129734
[TBL] [Abstract][Full Text] [Related]
7. Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop.
Greenland P; Michos ED; Redmond N; Fine LJ; Alexander KP; Ambrosius WT; Bibbins-Domingo K; Blaha MJ; Blankstein R; Fortmann SP; Khera A; Lloyd-Jones DM; Maron DJ; Min JK; Muhlestein JB; Nasir K; Sterling MR; Thanassoulis G
JACC Cardiovasc Imaging; 2021 Jul; 14(7):1454-1465. PubMed ID: 32950442
[TBL] [Abstract][Full Text] [Related]
8. Relation of Absence of Coronary Artery Calcium to Cardiovascular Disease Mortality Risk Among Individuals Meeting Criteria for Statin Therapy According to the 2018/2019 ACC/AHA Guidelines.
Rajan T; Rozanski A; Cainzos-Achirica M; Grandhi GR; Dardari ZA; Al-Mallah MH; Blankstein R; Miedema MD; Shaw LJ; Rumberger JA; Budoff MJ; Blaha MJ; Berman D; Nasir K
Am J Cardiol; 2020 Dec; 136():49-55. PubMed ID: 32941817
[TBL] [Abstract][Full Text] [Related]
9. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
11. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
[TBL] [Abstract][Full Text] [Related]
12. Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.
Whelton SP; McEvoy JW; Shaw L; Psaty BM; Lima JAC; Budoff M; Nasir K; Szklo M; Blumenthal RS; Blaha MJ
JAMA Cardiol; 2020 Sep; 5(9):1011-1018. PubMed ID: 32936272
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and All-Cause Mortality Risk by Coronary Artery Calcium Scores and Percentiles Among Older Adult Males and Females.
Wang FM; Rozanski A; Arnson Y; Budoff MJ; Miedema MD; Nasir K; Shaw LJ; Rumberger JA; Blumenthal RS; Matsushita K; Blaha MJ; Berman DS
Am J Med; 2021 Mar; 134(3):341-350.e1. PubMed ID: 32822664
[TBL] [Abstract][Full Text] [Related]
14. All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: A long-term, competing risk analysis in the Coronary Artery Calcium Consortium.
Blaha MJ; Cainzos-Achirica M; Dardari Z; Blankstein R; Shaw LJ; Rozanski A; Rumberger JA; Dzaye O; Michos ED; Berman DS; Budoff MJ; Miedema MD; Blumenthal RS; Nasir K
Atherosclerosis; 2020 Feb; 294():72-79. PubMed ID: 31784032
[TBL] [Abstract][Full Text] [Related]
15. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
Arps K; Rifai MA; Blaha MJ; Michos ED; Nasir K; Yeboah J; Budoff MJ; Blumenthal RS; Bittencourt MS; McEvoy JW
Am J Cardiol; 2019 Oct; 124(8):1198-1206. PubMed ID: 31416591
[TBL] [Abstract][Full Text] [Related]
17. Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium.
Peng AW; Mirbolouk M; Orimoloye OA; Osei AD; Dardari Z; Dzaye O; Budoff MJ; Shaw L; Miedema MD; Rumberger J; Berman DS; Rozanski A; Al-Mallah MH; Nasir K; Blaha MJ
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):83-93. PubMed ID: 31005541
[TBL] [Abstract][Full Text] [Related]
18. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
Circulation; 2019 Jun; 139(25):e1082-e1143. PubMed ID: 30586774
[TBL] [Abstract][Full Text] [Related]
19. Race/Ethnicity and the Prognostic Implications of Coronary Artery Calcium for All-Cause and Cardiovascular Disease Mortality: The Coronary Artery Calcium Consortium.
Orimoloye OA; Budoff MJ; Dardari ZA; Mirbolouk M; Uddin SMI; Berman DS; Rozanski A; Shaw LJ; Rumberger JA; Nasir K; Miedema MD; Blumenthal RS; Blaha MJ
J Am Heart Assoc; 2018 Oct; 7(20):e010471. PubMed ID: 30371271
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA).
Cainzos-Achirica M; Enjuanes C; Greenland P; McEvoy JW; Cushman M; Dardari Z; Nasir K; Budoff MJ; Al-Mallah MH; Yeboah J; Miedema MD; Blumenthal RS; Comin-Colet J; Blaha MJ
Atherosclerosis; 2018 Nov; 278():217-225. PubMed ID: 30312930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
